ContentsPage 14 - The climate crisis: what is it and is pharma to blame?Stefan Woxström at AstraZeneca tells Pharmafocus about the link between climate change and human healthPage 16 - Why modelling patient heterogeneity is crucial in drug developmentProf Shai Shen-Orr at CytoReason explores the need for patient heterogeneity and why this is so central to successful drug developmentPage 18 - How regulators are keeping pace with technologyFiona Maini from Medidata speaks about pharmaceutical regulation and the opportunities and challenges of digitalisation and a rapidly evolving industryPage 20 - Could climate change along with pandemics equal a recipe for disaster?Betsy Goodfellow considers the effects of climate change and how this could worsen, or even trigger, future pandemicsTop NewsPage 4 – FDA issues update around changes to COVID-19 vaccines’ EUAsPage 6 – Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s diseasePage 7 – Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuriesPage 9 – NICE recommends two CAR T treatments for blood cancers to the Cancer Drugs FundPage 10 – 3B Pharmaceuticals and Novartis enter into licensing agreement for FAP-targeting technologyOur TeamExecutive Director
PMGroup Worldwide Ltd
Karl EquiGroup Managing Editor
Iona Eversonieverson@pmlive.comEditorial Assistants
Betsy Goodfellow
betsy@pharmafile.com
James Spargo
james@samedanltd.comSales Manager
Eliot Hayneseliot@pharmafile.comDesign & Layout
Peter May
designer@samedanltd.comPharmafocus is published by:Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747www.pharmafile.comSubscriptions & Data ManagementCurwood CMS Tel: 01580 883840enquiries@c-cms.comISSN: 1465-5403Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.©2023 Samedan Ltd, Pharmaceutical PublishersThe opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.